Efficacy in Platinum-Sensitive vs Platinum-Resistant SCLC
Joshua K. Sabari, MD, discusses the antitumor activity of second-line lurbinectedin, noting an ORR of 45%, a median DOR of 6.2 months, and a median OS of 11.2 months in patients with relapsed SCLC, and emphasizes the need for further studies to validate these findings in those with longer chemotherapy-free intervals while considering factors that may lead to lurbinectedin’s use over chemotherapy in candidates for platinum rechallenge, as well as the potential role of G-CSFs for prophylaxis.
Video content above is prompted by the following:
Please discuss your impressions of the antitumor activity of second-line lurbinectedin in 60 of the 105 patients (57%) with relapsed SCLC and a CTFI interval of greater than 90 days after failure of a single previous line of platinum-based therapy:
• To what degree does an ORR of 45%, a median DOR of 6.2 months, and a median OS of 11.2 months encourage the use of lurbinectedin in patients with CTFIs either less than or greater than 180 days?
• Given that only 20 patients formed the basis for this subgroup analysis, what additional studies should be conducted to confirm the sustained antitumor efficacy of lurbinectedin among patients with relapsed SCLC who experience a protracted chemotherapy-free interval?
• What are the patient and/or disease factors that might motivate you to substitute lurbinectedin for chemotherapy in candidates eligible for platinum rechallenge?
• Is there a role for primary prophylaxis with G-CSFs in patients with relapsed SCLC?
